Quantcast
Connect with us

Drug company used ghost writers to author work bylined by academics, documents show

Published

on

According to newly released documents from GlaxoSmithKline, the pharmaceutical company often paid ghostwriters to pen medical studies, editorials and even a textbook that listed physicians as the authors.

The documents—some of which date back to late 1990s—were recently unsealed in litigation over a GlaxoSmithKline product. We saw them after they were attached to a letter released this week by a nonprofit watchdog group urging the National Institutes of Health to crack down on ghostwriting in medical academia. The documents and the letter by Project on Government Oversight together outline several examples of how a major drug company contributed to the funding, writing and approval of material published in medical journals and elsewhere.

ADVERTISEMENT

The textbook, published in 1999, listed two physician co-authors who at the time were chairs of the psychiatry departments at the medical schools of Stanford University and Emory University, the New York Times reported this week in a piece that focused only on the textbook. According to the Times, it’s the first instance where a book has been criticized for the same issues with ghostwriting and drug industry influence that have plagued medical journals.

A GSK spokesman told the Times that the company’s role was described in the book’s preface, which thanked the UK drugmaker (then known as SmithKline Beecham) for an “unrestricted educational grant” to the ghostwriting company, Scientific Therapeutics Information. Correspondence between a Scientific Therapeutics Information employee and one of the co-authors, however, shows the employee informing the stated author that she had “begun development of the text.” The employee, Sally Laden, also described her co-worker as the “primary technical writer” and manager for the project.

According to the documents, that same ghostwriter, Sally Laden, wrote an editorial published in 2003 in a medical journal with authorship attributed to two more doctors. One, Dwight Evans, is chairman of the psychiatry department of the University of Pennsylvania School of Medicine. His co-author, Dennis Charney, was head of a research program for the National Institute of Mental Health. (We’ve asked both for comment but have not yet received a response.) While Laden was credited for “editorial support” in the published article, another document seems to suggest she played more than just a supporting role. In an e-mail to a GlaxoSmithKline employee, she inquired about the status of her payment “for writing Dwight Evans’ editorial.”

Laden also helped a number of authors write a 2001 study that was funded by GlaxoSmithKline and concluded that a GSK antidepressant, Paxil, is “generally well tolerated and effective for [treating] major depression in adolescents.” Within a few years, problems with the study became apparent, and both UK regulators and the Food and Drug administration issued warningsabout Paxil. Glaxo, following the FDA’s warning, issued a letter in 2004 informing healthcare providers that Paxil is “not approved for use in the pediatric population, and clinical trials for PAXILfailed to demonstrate efficacy in pediatric depression.” [PDF]

Of course, just because a ghostwriter is involved doesn’t mean a study is flawed. An anonymous medical writer who has ghostwritten articles published in top medical journals gave an interview in October to the executive editor of a blog by the Society for Scholarly Publishing. In it, he argued that he provides “a service to those who need assistance presenting their findings to the scientific community”—in other words, to academics who “have a great study” but aren’t good writers.

ADVERTISEMENT

The ghostwriter also acknowledged, however, that writing services are often solicited by a pharmaceutical company first, and a manuscript is sometimes written before an academic “author” is found:

In my experience, the pharmaceutical company would pay a communications/marketing company to write the manuscript, who would then go out and find academics who would be willing to become the “authors” of the manuscript and paid an honorarium. I’ve worked with some authors who do absolutely nothing on the manuscript, requiring an additional ghostwriter to be hired, and still demand an honorarium for their time. These academics are willing to enter into this relationship because of the importance of authorship to their careers. You can’t entirely blame the pharma company. Universities encourage academics to play this game.

Earlier this year, a study in a scientific journal analyzed how medical ghostwriting works. It found that simply acknowledging ghostwriters “does not accurately reflect their authorship role.” It also found that, of the top 50 medical schools, only 10 explicitly ban ghostwriting.

ADVERTISEMENT

GlaxoSmithKline told the Times that in recent years, the company has tightened its internal guidelines for medical writers.

——

ADVERTISEMENT

By Marian Wang, ProPublica


Report typos and corrections to: [email protected].
READ COMMENTS - JOIN THE DISCUSSION
Continue Reading

Facebook

China deploys army medics to overwhelmed virus epicentre

Published

on

The central Chinese city at the epicentre of a SARS-like virus outbreak is building a second new hospital within weeks to treat cases, as angry patients faced hours-long waits at medical facilities overwhelmed with patients of a disease that has killed 41 and infected nearly 1,300.

The Chinese army has deployed medical specialists to help with treatment in the city of Wuhan, where a seafood and live animal market has been identified as the centre of the outbreak.

But people waiting at one hospital in the city were angry and frustrated.

"It takes at least five hours to see a doctor," one woman, who didn't want to be named, told AFP. "Nurses are brave but management is really messy."

Continue Reading

Facebook

Hong Kong declares Wuhan virus outbreak an ’emergency’

Published

on

Hong Kong on Saturday declared a new coronavirus outbreak as an "emergency" -- the city's highest warning tier -- as authorities ramped up measures to reduce the risk of further infections.

The announcement came as city leader Carrie Lam faced criticism in some quarters over her administration's response to the crisis.

Of the five people who have tested positive for the virus in Hong Kong so far, four arrived via a newly built high-speed train terminal which connects with the mainland.

That led to calls from some medical experts and politicians to limit, or even halt, arrivals from China, the epicentre of the outbreak with 41 people dead.

Continue Reading
 

Facebook

‘Nobody can leave’: Trapped Wuhan residents stock up

Published

on

Police at a roadblock on the outskirts of Wuhan turned away cars trying to leave the virus-stricken city on Saturday, as other anxious residents trapped inside spent the Lunar New Year stocking up on masks and medical supplies.

Authorities have prevented anyone from leaving Wuhan, the city of 11 million people at the heart of the viral outbreak which has so far infected nearly 1,300 people and killed 41 others.

AFP saw a steady trickle of cars approaching the roadblocks around 20 kilometres (12 miles) east of the city centre on Saturday morning, only for police in fluorescent jackets wearing masks to tell them to turn around.

Continue Reading
 
 
Help Raw Story Uncover Injustice. Join Raw Story Investigates for $1 and go ad-free.
close-image